Anzeige
Meldung des Tages: Milliarden aus Washington? Dieser kritische Rohstoff könnte der nächste Profiteur sein

Sandoz Group Aktie News

Aktie
WKN:  A3ETYB ISIN:  CH1243598427 US-Symbol:  SDZXF Branche:  Pharmazeutika Land:  Schweiz
65,76 €
-0,58 €
-0,87%
22:44:29 Uhr
Depot/Watchlist
Marktkapitalisierung *
27,76 Mrd. €
Streubesitz
46,54%
KGV
-
Dividende
0,60 CHF
Dividendenrendite
1,04%
neu: Nachhaltigkeits-Score
57 %
Index-Zuordnung
-
Weiter abwärts? Short handeln - Jetzt mit Hebel 6,00: MN207V
Werbung

Sandoz Group News

14.01.26 - EQS
Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes
Sandoz Group AG / Key word(s): Regulatory Approval Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership ...
12.01.26 - EQS
Sandoz CEO, speaking at 44th Annual J.P. Morgan Healthcare Conference, will outline plans to capitalize on unprecedented ’golden decade’ of affordable medicines opportunity
Sandoz Group AG / Key word(s): Conference Sandoz CEO, speaking at 44th Annual J.P. Morgan Healthcare Conference, will outline plans to capitalize on unprecedented ’golden ...
08.12.25 - EQS
Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership
Sandoz Group AG / Key word(s): Acquisition Sandoz completes strategic acquisition of Just-​Evotec Biologics EU SAS, asserting biosimilars leadership 08.12.2025 / 07:00 CET/CEST
01.12.25 - EQS
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients
Sandoz Group AG / Key word(s): Market Launch Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-​related bone disease and ...
24.11.25 - EQS
Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases
Sandoz Group AG / Key word(s): Market Launch Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases 24-Nov-2025 ...
17.11.25 - EQS
Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
Sandoz Group AG / Key word(s): Market Launch Sandoz launches TYRUKO® (natalizumab-​sztn) in US, as first and only multiple sclerosis biosimilar 17-Nov-2025 / 07:00 CET/CEST ...
12.11.25 - EQS
Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab
Sandoz Group AG / Key word(s): Agreement Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab 12.11.2025 / 07:35 CET/CEST
04.11.25 - EQS
Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse
Sandoz Group AG / Key word(s): Agreement Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-​Evotec Biologics EU SAS in Toulouse 04.11.2025 ...
30.10.25 - EQS
Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded
Sandoz Group AG / Key word(s): Sales Result/9 Month figures Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded 30-Oct-2025 / 07:00 ...
09.09.25 - EQS
Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar
Sandoz Group AG / Key word(s): Agreement Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar 09-Sep-2025 / 07:00 ...
28.08.25 - wallstreetONLINE Redaktion
Neustart an der Börse: Milliardenwert in Gefahr: Schafft dieser Pharmakonzern den IPO trotz Schulden?
Nach dem geplatzten Frühstart setzt Stada erneut auf ein IPO. Anleger müssen entscheiden, ob sie trotz Milliardenverschuldung an das Börsen-​Comeback glauben.Der hessische ...
28.08.25 - EQS
Sandoz launches rivaroxaban in Germany, expanding access to high-quality antithrombotic treatment options
Sandoz Group AG / Key word(s): Product Launch Sandoz launches rivaroxaban in Germany, expanding access to high-​quality antithrombotic treatment options 28.08.2025 / 07:00 ...
12.08.25 - GlobeNewswire
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
MEDIA RELEASE
07.08.25 - GlobeNewswire
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
30.07.25 - dpa-AFX
Evotec verkauft Standort in Frankreich an Sandoz - erhofft sich Margensteigerung
Der mitten in einem tiefgreifenden Umbau steckende Biotechkonzern Evotec will einen Standort in Toulouse an den Pharmakonzern Sandoz verkaufen. Eine entsprechende nicht ...
30.07.25 - GlobeNewswire
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
04.07.25 - dpa-AFX
AKTIEN IM FOKUS: Pharma-Werte steigen in Zürich - Kreise: Ausnahme von Zöllen
Die Aussicht auf einen Deal im Handelskonflikt zwischen den USA und der Schweiz hat am Freitag in Zürich die Aktien von Pharmaunternehmen angetrieben. Grund ist ein Bericht ...
01.07.25 - GlobeNewswire
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
MEDIA RELEASE
02.06.25 - dpa-AFX
Sandoz bringt erste austauschbare Denosumab-Biosimilars auf den US-Markt
Der Pharmakonzern Sandoz hat den Marktstart von zwei neuen Biosimilars in den USA bekannt gegeben. Wyost und Jubbonti, beides Nachahmerprodukte des Wirkstoffs ...
02.06.25 - GlobeNewswire
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

Newssuche

Videos

newspaper
20:00 Uhr
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »